Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 544 results for iv

  1. Tegaderm CHG securement dressing for vascular access sites (MIB231)

    NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .

  2. Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

  3. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

  4. Assessment and monitoring:- What is the incidence of complications during, and as a consequence of, IV fluid therapy?

    monitoring:- What is the incidence of complications during, and as a consequence of, IV fluid therapy? Any explanatory notes(if...

  5. Fluid balance charts:- For children and young people receiving IV fluids, does the use of a standardised national fluid balance chart reduce the rate of complications arising as a result of prescription and/or administration errors?

    Question Fluid balance charts:- For children and young people receiving IV fluids, does the use of a standardised national fluid balance...

  6. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)

    Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.

  7. Diverticular disease: diagnosis and management (NG147)

    This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.

  8. The Implementation of Site Rite 8 and Sherlock 3CG Tip Confirmation System for PICC Placement in the Radiology Based Vascular Access Service

    more timely service through bedside placements, reduces the risk of missed IV doses due to lack of venous access, reduces portering time...

  9. CKS end user licence agreement

    CKS end user licence agreement

  10. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  11. Managing anaemia: For adults, children and young people with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)?

    with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost...

  12. Febrile Neutropenia Patient Group Direction: Improving treatment and sepsis management in paediatric oncology patients in Wales

    policies being in place, 62% of the audit sample did not receive the recommended IV antibiotic treatment within 1 hour of arrival to the...

  13. Radiofrequency treatment for haemorrhoids (IPG589)

    Evidence-based recommendations on radiofrequency treatment for haemorrhoids in adults. This involves using radiofrequency energy to shrink the haemorrhoids.

  14. Intrathecal baclofen:- What is the clinical and cost effectiveness of continuous pump-administered intrathecal baclofen compared with usual care in children and young people who are at Gross Motor Function Classification System (GMFCS) level IV or V?

    people who are at Gross Motor Function Classification System (GMFCS) level IV or V? Any explanatory notes(if applicable) Why this is...

  15. Ovarian cancer: recognition and initial management (CG122)

    This guideline covers detecting, diagnosing and treating women (18 years and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.